B 4 contributes to inflammatory cell chemotaxis to the bronchi and alveoli, whereas the cysteinyl leukotriene C 4 , leukotriene D 4 , and leukotriene E 4 increase vascular permeability and smooth muscle cell contraction, leading to bronchoconstriction and vasoconstriction in patients with asthma. 6, 8 Increased levels of leukotriene B 4 and cysteinyl leukotrienes in patients with asthma may promote AAA development by increasing aortic wall inflammatory cell accumulation and expansion.
This study probed this possible link between asthma or reversible obstructive airway disease (ROPD) and AAA in 15 942 individuals with AAA from the Danish National Registry of Patients (DNRP), and 18 749 men with both AAA and non-AAA controls from the Viborg Vascular (VIVA) screening trial.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Table 1 shows the baseline characteristics of the participants (patients admitted with ruptured AAA [rAAA] ) and controls (patients admitted with nonruptured AAA) from the DNRP population. A total of 15 942 patients with AAA were selected, 4497 of whom had rAAA (81.2% males and 18.8% females). The 11 445 AAA controls were age-and sex-matched with the 4497 rAAA cases. Of the 15 942 patients with AAA, 514 had hospital-diagnosed asthma including outpatients, from which 146 had rAAA and 368 did not. At time of AAA admission, anti-asthma drug users comprised 13.9% of the cases. Of these, 83.9% used selective β-2-adrenergic receptor agonists, 28.1% used anticholinergic agents, 35 .0% used inhaled glucocorticoids, and 11.0% used theophylline. Individuals in this study included 81.2% men, and the median age was 74.0 (interquartile range, 68.1-79.6) years. Table 1 shows patient information with preadmission medications within 90 days of the index date, including bronchodilator (with selective β-2-adrenergic receptor agonists and anticholinergic agents) or inhaled glucocorticoids. Table 1 also includes patient to general practitioner interaction information, household income, and marital status.
Results

DNRP Population
Risk of AAA Rupture in Patients With Asthma
In 15 942 patients with AAA aged 50 and older, we defined asthma in those who were hospital-diagnosed including outpatient contacts, used bronchodilators containing either β-2-adrenergic receptor agonists or anticholinergic agents or both, or were nonbronchodilator users but prescribed other asthmabased medications in Denmark, including inhaled glucocorticoids and theophylline. Patients with asthma may have also received other treatments, such as oral glucocorticoids. Patients with nonasthmatic diseases may have also used these drugs and, therefore, were not included in the rAAA risk assessment.
A total of 146 patients with rAAA had a history of hospital-diagnosed asthma, among which 26 patients with rAAA were diagnosed with asthma <360 days and 22 patients <180 days before the index date. When all 146 ever rAAA patients were compared with 654 age-and sex-matched AAA controls, asthma did not associate with AAA rupture before (odds ratio Table 2 ).
The patient group that consisted of users of bronchodilators (β-2-adrenergic receptor agonists or anticholinergic agents or both) was also analyzed based on the time from the index date, including those who ever used and used within 360, 180, and 90 days of the index date. Recent use of bronchodilators correlated with a higher risk of AAA rupture, increasing with the proximity of use to the index date. OR values ranged from 1.10 (95% CI: Table 2) .
We separated patients with AAA who received prescriptions for anti-asthmatic drugs, including β-2-adrenergic receptor agonists, anticholinergic agents, inhaled glucocorticoids, or theophylline by the prescription date to the index date, as ever, < 90, 180, and 360 days. AAA rupture risk increased from ever prescribed, within 360 days, within 180 days, to within 90 days from the index date, among all 4 asthmatic medications. For example, among rAAA patients with a prescription dated <90 days before the index date, the OR values before adjustment were 1.35 (95% CI: 1. 
001).
External adjustment helps to address the missing information on potential confounders. [9] [10] [11] Information regarding cigarette smoking from the DNRP population remains incomplete, which may confound the risk assessment of asthma on AAA. Consequently, the respective observed proportion among AAA patients of smokers with or without use of bronchodilators permitted external adjustment for smoking in the DNRP. This adjustment increased the relative rAAA risk estimate to an adjusted OR of 1.46 (95% CI: 1.31-1.62; P<0.001) from 1.31 (95% CI: 1.18-1.46; P<0.001) associated with bronchodilator use within 90 days of index date (Table 2 ). This increase in the relative risk results from an observed lower proportion of smokers among users of bronchodilators compared with nonusers in the VIVA trial.
VIVA Screening Trial
The VIVA screening trial contains both AAA (n=619) and non-AAA patients with complete cigarette smoking history. This group differs from the DNRP population, which contains only patients with AAA. The VIVA population enabled testing for potential confounding by cigarette smoking of the association of AAA with asthma or ROPD. Logistic regression analysis demonstrated that use of bronchodilators, including anti-asthmatic medications with β-2-adrenergic receptor agonists or use of glucocorticoids for inhalation or as tablets, associated with a 45% higher risk of an AAA (OR=1. 45 (Table 3 , model 5). In this VIVA population, except for diabetes mellitus, all other potential confounders (smoking, hypertension, blood pressure, body mass index, and age) were independently associated with the risk of AAA (Table 3 ). Collection of plasma samples from 500 cases and 200 ageand sex-matched controls helped to test whether the plasma YKL-40 (chitinase 3-like protein 1) associates with AAA development. YKL-40 acts as a biomarker of type 2 inflammation, and its expression remains elevated in neutrophils from patients with type 2 diabetes mellitus, in human cancer cells, and in the plasma samples from patients with cardiovascular events. [12] [13] [14] Evidence suggests, however, that YKL-40 also correlates with acute exacerbation, total serum IgE, the percentage of peripheral blood eosinophils, and lung function among patients with asthma, [15] [16] [17] [18] although a current asthma-specific biomarker does not exist. Therefore, YKL-40 provides strong but not irrefutable evidence for asthma. Results showed significantly higher plasma YKL-40 levels from patients with AAA (n=500) than from controls (n=200; mean±standard deviation, 106.6±102.8 versus 91.9±147.6 μg/L; P<0.001, Wilcoxon rank sum test). Patients who used bronchodilators also had significantly higher plasma YKL-40 levels than those who did not use bronchodilators (mean±standard deviation, 122.0±129.8 versus 100.7±116.9 μg/L; P=0.049, Wilcoxon rank sum test). *Number of case sex-and age-matched patients with AAA may be used for more than 1 category. †Adjusted for myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, diabetes mellitus with or without complications, and moderate to severe renal disease; concomitant drug use (ACE [angiotensin-converting enzyme]-inhibitors, angiotensin II antagonists, aldosterone antagonists, β-2-adrenergic receptor blocking agents, calcium antagonists, statins, antiplatelet therapy, antidiabetic therapy, corticosteroids, and NSAIDs); the number of visits to a general practitioner in the year before admission, income, and marital status.
‡Since January 1, 1977 . §Patients were among the ever group. ¶Bronchodilators with selective β-2-adrenergic receptor agonists and anticholinergics. #Since January 1, 1995. **Patients prescribed selective β -2-adrenergic receptor agonists and anticholinergics were among the bronchodilator use group. Downloaded from http://ahajournals.org by on December 19, 2019 
Discussion
This study established an association between AAA and asthma or ROPD in humans. Data collected from the large population of Danish patients with AAA in DNRP showed that a hospital diagnosis of asthma or a recently filled prescription of an anti-asthmatic drug associated with an increased risk of admission with rAAA compared with admission with intact AAA, both before and after adjusting for AAA comorbidities and relevant medications. Moreover, an asthma diagnosis or the use of bronchodilators or other anti-asthmatic drug prescriptions closer to the date of admission with AAA correlated directly with a higher risk of aortic rupture. The results remained robust after adjusting for a wide range of relevant possible confounders. The late onset of asthma and medication use associated with aortic rupture relates to findings from a recent case-control study of 50 patients with childhood onset of asthma and 57 healthy children in which earlier onset of asthma during childhood did not affect abdominal aortic stiffness parameters, including aortic distensibility, aortic strain, pressure strain elastic modulus, and pressure strain normalized by diastolic pressure. 19 The lack of information on cigarette smoking among the DNRP population could confound our conclusion, as smoking is a known independent risk factor for rAAA. 20 Indeed, external adjustment of the DNRP data of smoking habits among patients with AAA using or not using bronchodilators only increased the independent relative risk of rupture by an asthma diagnosis or the use of bronchodilators or other anti-asthmatic drug prescriptions. In addition, supplemental analyses from the VIVA trial 21 showed that adjustment for smoking did not change the independent estimates of risk of AAA among bronchodilator users, suggesting that bronchodilator use did not associate with smoking status. The risk of AAA among patients with asthma remained 45% higher than that of patients with nonasthma.
Prior studies established an association between AAA and COPD. [22] [23] [24] [25] Although asthma and COPD can overlap in some patients, the majority of patients with asthma do not have COPD. A diagnosis of asthma does not necessarily lead to hospitalization or outpatient contact. This potential limitation led us to define asthma as those patients who had ROPD and recorded the use of bronchodilators, as reported recently in an atherosclerosis risk-assessment study. 26 Higher OR of aortic rupture from AAA patients with hospital-diagnosed asthma were identified than those from AAA patients who received anti-asthmatic medication (Figure; Table 2 ), suggesting that we have underestimated the risk of asthma on AAA by defining asthma as the recorded use of bronchodilators and anti-asthmatic drugs (β-2-adrenergic receptor agonists, anticholinergic medications, inhaled glucocorticoids, and xanthines). The strengths of this study include the use of 2 relatively large population-based cohorts, which support both the association of ROPD with the risk of having an AAA and the rupture of an existing AAA. The interrogation of population-based cohorts minimizes the risk of selection bias, and the use of the drug registry minimizes the risk of misclassification as no relevant bronchodilator agent is given without a recorded prescription. Yet the inclusion in this group of users both patients with asthma and those with COPD with some reversible obstructive component presents a limitation. In Denmark, the number of prescriptions for inhalated bronchodilating agents for indications other than asthma or ROPD remains low, but the possibility exists that a small portion of patients using inhalated bronchodilator agents have COPD without a reversible component, 25, 27, 28 which may confound our conclusion. Consequently, a subgroup analysis of patients with or without a diagnosis of asthma showed an increase in the relative risk of rupture to about twice as high a risk of rupture. This finding strongly supports the primary hypothesis of this study because this analysis concentrates on a severe risk of misclassification as many patients with asthma are solely managed by the general practitioners, introducing a bias toward the null hypothesis in this subgroup analysis.
Several recent studies have provided direct and indirect evidence that link the risk of asthma on human AAA and rupture. In apolipoprotein E-deficient (Apoe -/-) mice, development of allergic airway inflammation significantly enlarged atherosclerotic plaques and increased lesion inflammation. 29 Recent data from the Multi-Ethnic Study of Atherosclerosis show that patients with asthma who use inhaled corticosteroids, leukotriene inhibitors, or oral corticosteroids have significantly higher plasma C-reactive protein and fibrinogen concentrations, lower unadjusted cardiovascular disease-free survival rate, and higher cardiovascular disease risk than patients with asthma who do not use these medications or those without asthma. 26 Although atherosclerosis may not underlie all AAA, atherosclerosis usually accompanies aneurysmal dilation 30 and constitutes a long-recognized risk factor of AAA. 31 We recently demonstrated directly that the development of allergic airway inflammation in mice doubled the size of experimental AAA, regardless of whether allergic airway inflammation began before, after, or during AAA formation. 32 The mechanisms by which humans and mice develop AAA and asthma or allergic lung inflammation can differ, but we found a comparable increase of plasma IgE in mice that developed AAA or allergic lung inflammation. A synergistic increase of plasma IgE in mice with both AAA and allergic lung inflammation 32 and beneficial effects on both human asthma and mouse AAA development of targeting IgE 5, 33 support the contribution of IgE to both diseases.
As discussed, inflammatory cell accumulation in the airway and aortic lesions accompanies both asthma and AAA. These leukocytes may participate in the pathogenesis of these 2 seemingly unrelated diseases. In the asthmatic lung, mast cells release cytokines, proteases, and histamine and, thus, stimulate airway tissue remodeling, mucus secretion, smooth muscle contraction and vasodilatation, and immune cell activation. 34, 35 Sputum from patients with asthma contains significantly increased neutrophil and eosinophil numbers. 36 Eosinophils mediate airway inflammation in mild and moderate atopic asthma, whereas neutrophils predominate in nonatopic and severe asthma. [37] [38] [39] The polymorphonuclear leukocytes release neutrophil elastase that may mediate airway goblet cell hyperplasia, degranulation, and mucous plugging. 40 Although a direct role of eosinophils in AAA remains untested, either mast cells or neutrophils promote AAA development. Mast cells contribute to AAA by releasing cytokines (eg, interleukin 6 and interferon-γ) and proteases (eg, chymase and tryptase) that can activate vascular cells and breakdown the arterial extracellular matrix. 4, 41, 42 Neutrophils also release proteases that can contribute to arterial wall tissue remodeling. 43, 44 These shared mechanisms likely contribute to crosstalk between these diseases, a hypothesis that merits further investigation.
Finally, a risk of confounding exists-especially in the DNRP analyses, which lacks individual data regarding smoking status. Yet, the VIVA study indicates that users of bronchodilating drugs smoke less than nonusers. Although we adjusted for almost all known potential confounders, the risk of residual confounding always remains an issue in observational studies.
In conclusion, this observational study conducted in 2 independent cohorts established a new link between the allergic asthma and AAA. Because allergic inflammation with elevated plasma IgE may promote AAA pathogenesis, 5 other allergic inflammatory diseases, such as atopic dermatitis, allergic rhinitis, and several ocular allergic diseases, may carry similar risks as asthma for AAA formation and rupture. The findings from this study highlight a commonality in the inflammatory pathways involved in AAA and other prevalent and seemingly unrelated diseases. The results have implications for the development of much needed advances in the prevention, screening criteria, and treatment of AAA, common conditions for which we currently lack sufficiently effective approaches.
